A comprehensive view of Generics/Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Commentary: If Medicare purchased generic drugs at prices charged by Mark Cuban Cost Plus Drug Company in 2020, it would have saved US$3.6B on 77 of 89 drugs, finds report; analysis shows distributing generic drugs can be costlier than making drug itself
Published: June 20, 2022 by Reuters
Prices of name-brand epilepsy drugs rose 277% in past eight years, while cost of generics dropped 42%; percentage of brand-name drugs prescribed for epilepsy drops from 56% in 2008 to 14% in 2018
Published: June 20, 2022 by The Breeze (James Madison University)
Fitch: Generic drug manufacturers post mixed Q1 results, ranging from negative to double-digit growth; supply chain bottlenecks to pose risks over rest of 2022, and inflationary pressures will further weigh on demand and innovation in short-to-medium term
Published: June 09, 2022 by Fitch Solutions Sector Intelligence
Accord Healthcare releases generic Vilazodone serotonin modulator, a therapeutic equivalent of Allergan's VIIBRYD, in 10 mg, 20 mg, 40 mg oral tablets to treat major depressive disorder; MDD affects 5% of adults worldwide
Published: June 09, 2022 by PR Newswire
FDA approves Eugia Pharma’s injectable leuprolide acetate bioequivalent of AbbVie’s Lupron to treat advanced prostate cancer; product market estimated at US$83M annually
Published: June 08, 2022 by Business Line

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count